Black Rock Inc. Vincerx Pharma, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Vincerx Pharma, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 47,080 shares of VINC stock, worth $7,062. This represents 0.0% of its overall portfolio holdings.

Number of Shares

47,080

Previous 47,080 -0.0%

Holding current value

$7,062

Previous $238,000 84.03%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.07 - $8.06 $18,381 - $138,462	-17,179 Reduced 26.73%	47,080 $238,000
Q3 2023 Nov 13, 2023	SELL	$0.66 - $1.38 $1,106 - $2,312	-1,676 Reduced 2.54%	64,259 $64,000
Q2 2023 Aug 11, 2023	SELL	$0.88 - $1.9 $43,051 - $92,951	-48,922 Reduced 42.59%	65,935 $85,000
Q1 2023 May 12, 2023	SELL	$0.9 - $1.51 $21,770 - $36,525	-24,189 Reduced 17.4%	114,857 $119,000
Q4 2022 Feb 13, 2023	BUY	$0.64 - $1.32 $176 - $364	276 Added 0.2%	139,046 $141,000
Q3 2022 Nov 14, 2022	SELL	$0.0 - $1.72 $0 - $6,224	-3,619 Reduced 2.54%	138,770 $191,000
Q2 2022 Aug 12, 2022	SELL	$0.0 - $0.0 $0 - $0	-628,615 Reduced 81.53%	142,389 $188,000
Q1 2022 May 12, 2022	SELL	$0.0 - $0.0 $0 - $0	-1,274 Reduced 0.16%	771,004 $3.08 Million
Q4 2021 Feb 10, 2022	BUY	$0.0 - $0.0 $0 - $0	44,187 Added 6.07%	772,278 $7.87 Million
Q3 2021 Nov 09, 2021	BUY	$0.0 - $0.0 $0 - $0	401,857 Added 123.18%	728,091 $11.8 Million
Q2 2021 Aug 11, 2021	BUY	$0.0 - $27.0 $0 - $8.81 Million	326,234 New	326,234 $4.24 Million

Others Institutions Holding VINC

# of Institutions

Shares Held

11M

Call Options Held

Put Options Held

View Full List

About Vincerx Pharma, Inc.

Ticker VINC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,189,800
Market Cap $3.18M
Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...

More about VINC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account